LUCIANO FERREIRA DRAGER

(Fonte: Lattes)
Índice h a partir de 2011
37
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/63, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2020 ×

Resultados de Busca

Agora exibindo 1 - 10 de 19
  • conferenceObject
    Effects of CPAP on Metabolic Syndrome in Patients with Obstructive Sleep Apnea: The TREATOSA-MS Randomized Controlled Trial
    (2020) GIAMPA, S. Q.; FREITAS, L. S.; FURLAN, S. F.; MACEDO, T. A.; LEBKUCHEN, A.; CARDOZO, K. H. M.; MARTINS, F. C.; AZAM, I. F. B.; COSTA-HONG, V.; BAPTISTA, M. L.; ROCHITTE, C. E.; BORTOLOTTO, L. A.; LORENZI-FILHO, G.; DRAGER, L. F.
  • conferenceObject
    IS THERE ANY VALUE FOR HOSPITALIZATION FOR CHECKING MEDICATION ADHERENCE DUE TO RESISTANT AND REFRACTORY HYPERTENSION SUSPICIOUS? IMPLICATIONS FOR MID-TERM FOR BLOOD PRESSURE CONTROL.
    (2020) ABREU, Andrea Pio de; TRANI, Fernanda; VIEIRA, Giovanio; BORTOLOTTO, Luiz Aparecido; DRAGER, Luciano Ferreira
  • conferenceObject
  • article 0 Citação(ões) na Scopus
    Posicionamento Brasileiro sobre Hipertensao Arterial Resistente - 2020 (vol 114, pg 576, 2020)
    (2020) YUGAR-TOLEDO, Juan Carlos; MORENO JUNIOR, Heitor; GUS, Miguel; ROSITO, Guido Bernardo Aranha; SCALA, Luiz Cesar Nazario; MUXFELDT, Elizabeth Silaid; ALESSI, Alexandre; BRANDAO, Andrea Araujo; MOREIRA FILHO, Osni; FEITOSA, Audes Diogenes de Magalhaes; PASSARELLI JUNIOR, Oswaldo; SOUZA, Dilma do Socorro Moraes de; AMODEO, Celso; BARROSO, Weimar Kunz Sebba; GOMES, Marco Antonio Mota; PAIVA, Annelise Machado Gomes de; BARBOSA, Eduardo Costa Duarte; MIRANDA, Roberto Dischinger; VILELA-MARTIN, Jose Fernando; NADRUZ JUNIOR, Wilson; RODRIGUES, Cibele Isaac Saad; DRAGER, Luciano Ferreira; BORTOLOTTO, Luiz Aparecido; CONSOLIM-COLOMBO, Fernanda Marciano; SOUSA, Marcio Goncalves de; BORELLI, Flavio Antonio de Oliveira; KAISER, Sergio Emanuel; SALLES, Gil Fernando; AZEVEDO, Maria de Fatima de; MAGALHAES, Lucelia Batista Neves Cunha; POVOA, Rui Manoel dos Santos; MALACHIAS, Marcus Vinicius Bolivar; NOGUEIRA, Armando da Rocha; JARDIM, Paulo Cesar Brandao Veiga; JARDIM, Thiago de Souza Veiga
  • article 58 Citação(ões) na Scopus
    Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension A Randomized Clinical Trial
    (2020) SCHIAVON, Carlos A.; BHATT, Deepak L.; IKEOKA, Dimas; V, Eliana Santucci; SANTOS, Renato Nakagawa; DAMIANI, Lucas P.; OLIVEIRA, Juliana D.; V, Rachel Helena Machado; HALPERN, Helio; MONTEIRO, Frederico L. J.; NOUJAIM, Patricia M.; V, Ricardo Cohen; SOUZA, Marcio G. de; AMODEO, Celso; BORTOLOTTO, Luiz A.; BERWANGER, Otavio; CAVALCANTI, Alexandre B.; DRAGER, Luciano F.
    Background: Midterm effects of bariatric surgery on patients with obesity and hypertension remain uncertain. Objective: To determine the 3-year effects of Roux-en-Y gastric bypass (RYGB) on blood pressure (BP) compared with medical therapy (MT) alone. Design: Randomized clinical trial. (ClinicalTrials.gov: NCT01784848) Setting: Investigator-initiated study at Heart Hospital (HCor), Sao Paulo, Brazil. Participants: Patients with hypertension receiving at least 2 medications at maximum doses or more than 2 medications at moderate doses and with a body mass index (BMI) between 30.0 and 39.9 kg/m(2) were randomly assigned (1:1 ratio). Intervention: RYGB plus MT or MT alone. Measurements: The primary outcome was at least a 30% reduction in total number of antihypertensive medications while maintaining BP less than 140/90 mm Hg. Key secondary outcomes were number of antihypertensive medications, hypertension remission, and BP control according to current guidelines (<130/80 mm Hg). Results: Among 100 patients (76% female; mean BMI, 36.9 kg/m(2) [SD, 2.7]), 88% from the RYGB group and 80% from the MT group completed follow-up. At 3 years, the primary outcome occurred in 73% of patients from the RYGB group compared with 11% of patients from the MT group (relative risk, 6.52 [95% CI, 2.50 to 17.03]; P < 0.001). Of the randomly assigned participants, 35% and 31% from the RYGB group and 2% and 0% from the MT group achieved BP less than 140/90 mm Hg and less than 130/80 mm Hg without medications, respectively. Median (interquartile range) number of medications in the RYGB and MT groups at 3 years was 1 (0 to 2) and 3 (2.8 to 4), respectively (P < 0.001). Total weight loss was 27.8% and -0.1% in the RYGB and MT groups, respectively. In the RYGB group, 13 patients developed hypovitaminosis B-12 and 2 patients required reoperation. Limitation: Single-center, nonblinded trial. Conclusion: RYGB is an effective strategy for midterm BP control and hypertension remission, with fewer medications required in patients with hypertension and obesity.
  • article 26 Citação(ões) na Scopus
    Severe obstructive sleep apnea is associated with circulating microRNAs related to heart failure, myocardial ischemia, and cancer proliferation
    (2020) FREITAS, Lunara S.; SILVEIRA, Andre C.; MARTINS, Franco C.; COSTA-HONG, Valeria; LEBKUCHEN, Adriana; CARDOZO, Karina H. M.; BERNARDES, Fernanda M.; BORTOLOTTO, Luiz A.; LORENZI-FILHO, Geraldo; OLIVEIRA, Edilamar M.; DRAGER, Luciano F.
    Purpose Obstructive sleep apnea (OSA) is associated with multiple comorbid conditions including cardiovascular diseases and cancer. There is a growing interest in exploring biomarkers to understand the related mechanisms and improve the risk stratification of OSA. Circulating microRNAs (miRNAs) are single noncoding strands of nearly 22 nucleotides that posttranscriptionally regulate target gene expression. Our aim was to identify miRNA profiles associated with OSA. Methods We studied 48 male subjects, mostly Caucasian (63%) and overweight, divided by polysomnography into the no OSA control group (n = 6), mild OSA group (n = 12), moderate OSA group (n = 15), and severe OSA group (n = 15). The study groups were matched for age, body mass index (BMI), and body fat composition. miRNA profiles were measured from peripheral whole blood using two steps: (1) microarray analysis comprising more than 2500 miRNAs in a subsample of 12 subjects (three from each group); and (2) validation phase using real-time quantitative polymerase chain reaction (RTqPCR). Results The microarray assessment identified 21 differentially expressed miRNAs among the groups. The RT-qPCR assessment showed that miR-1254 and miR-320e presented a gradual increase in expression parallel to OSA severity. Linear regression analysis showed that severe OSA was independently associated with miR-1254 (ss = 68.4; EP = 29.8; p = 0.02) and miR-320e (ss = 76.1; EP = 31.3; p = 0.02). Conclusion Severe OSA is independently associated with miRNAs that are involved in heart failure (miR-1254), myocardial ischemia/reperfusion (miR-320e), and cell proliferation in some cancer types (miR-1254 and miR-320e). Future investigations addressing whether these miRs may provide prognostic information in OSA are needed.
  • conferenceObject
    The Role of Fluid Accumulation in Acute Weight Gain During CPAP Treatment in Patients with Obstructive Sleep Apnea
    (2020) SILVA, S.; GRAD, G. F.; DRAGER, L. F.; ALBUQUERQUE, A. L.; MELO, C. M. de; LORENZI-FILHO, G.; GENTA, P.
  • article 35 Citação(ões) na Scopus
    Continuous Positive Airway Pressure Treatment, Glycemia, and Diabetes Risk in Obstructive Sleep Apnea and Comorbid Cardiovascular Disease
    (2020) LOFFLER, Kelly A.; HEELEY, Emma; FREED, Ruth; MENG, Rosie; BITTENCOURT, Lia R.; CARVALHO, Carolina C. Gonzaga; CHEN, Rui; HLAVAC, Michael; LIU, Zhihong; LORENZI-FILHO, Geraldo; LUO, Yuanming; MCARDLE, Nigel; MUKHERJEE, Sutapa; YAP, Hooi Shan; ZHANG, Xilong; PALMER, Lyle J.; ANDERSON, Craig S.; MCEVOY, R. Doug; DRAGER, Luciano F.
    OBJECTIVE Despite evidence of a relationship among obstructive sleep apnea (OSA), metabolic dysregulation, and diabetes, it is uncertain whether OSA treatment can improve metabolic parameters. We sought to determine effects of long-term continuous positive airway pressure (CPAP) treatment on glycemic control and diabetes risk in patients with cardiovascular disease (CVD) and OSA. RESEARCH DESIGN AND METHODS Blood, medical history, and personal data were collected in a substudy of 888 participants in the Sleep Apnea cardioVascular Endpoints (SAVE) trial in which patients with OSA and stable CVD were randomized to receive CPAP plus usual care, or usual care alone. Serum glucose and glycated hemoglobin A(1c)(HbA(1c)) were measured at baseline, 6 months, and 2 and 4 years and incident diabetes diagnoses recorded. RESULTS Median follow-up was 4.3 years. In those with preexisting diabetes (n= 274), there was no significant difference between the CPAP and usual care groups in serum glucose, HbA(1c), or antidiabetic medications during follow-up. There were also no significant between-group differences in participants with prediabetes (n= 452) or new diagnoses of diabetes. Interaction testing suggested that women with diabetes did poorly in the usual care group, while their counterparts on CPAP therapy remained stable. CONCLUSIONS Among patients with established CVD and OSA, we found no evidence that CPAP therapy over several years affects glycemic control in those with diabetes or prediabetes or diabetes risk over standard-of-care treatment. The potential differential effect according to sex deserves further investigation.
  • article 14 Citação(ões) na Scopus
    Brazilian Position Statement on Resistant Hypertension-2020
    (2020) YUGAR-TOLEDO, Juan Carlos; MORENO JUNIOR, Heitor; GUS, Miguel; ROSITO, Guido Bernardo Aranha; SCALA, Luiz Cesar Nazario; MUXFELDT, Elizabeth Silaid; ALESSI, Alexandre; BRANDAO, Andrea Araujo; MOREIRA FILHO, Osni; FEITOSA, Audes Diogenes de Magalhaes; PASSARELLI JUNIOR, Oswaldo; SOUZA, Dilma do Socorro Moraes de; AMODEO, Celso; BARROSO, Weimar Kunz Sebba; GOMES, Marco Antonio Mota; PAIVA, Annelise Machado Gomes de; BARBOSA, Eduardo Costa Duarte; MIRANDA, Roberto Dischinger; VILELA-MARTIN, Jose Fernando; NADRUZ JUNIOR, Wilson; RODRIGUES, Cibele Isaac Saad; DRAGER, Luciano Ferreira; BORTOLOTTO, Luiz Aparecido; CONSOLIM-COLOMBO, Fernanda Marciano; SOUSA, Marcio Goncalves de; BORELLI, Flavio Antonio de Oliveira; KAISER, Sergio Emanuel; SALLES, Gil Fernando; AZEVEDO, Maria de Fatima de; MAGALHAES, Lucelia Batista Neves Cunha; POVOA, Rui Manoel dos Santos; MALACHIAS, Marcus Vinicius Bolivar; NOGUEIRA, Armando da Rocha; JARDIM, Paulo Cesar Brandao Veiga; JARDIM, Thiago de Souza Veiga
  • article 0 Citação(ões) na Scopus
    Bariatric Surgery for Resistant Hypertension: Working in Progress!
    (2020) SCHIAVON, Carlos A.; PIO-ABREU, Andrea; DRAGER, Luciano F.
    Purpose of ReviewTo discuss the recent evidence pointing the benefits of the bariatric surgery on blood pressure control in patients with obesity and hypertension. Particular focus is devoted to discuss the potential impact on resistant hypertension.Recent FindingsGrowing evidence suggest that bariatric surgery promotes not only a significant reduction in the anti-hypertensive medication while maintained blood pressure control but also a significant proportion of hypertension remission as compared to the usual care. In a sub-analysis of the GATEWAY trial using both office and 24-h ambulatory blood pressure monitoring, the prevalence of resistant hypertension significantly decreased after 12 months in the surgical group whereas the numbers remained stable in the control group.SummaryDespite the lack of robust evidence, preliminary findings underscore the strong need to explore the potential role of bariatric surgery on resistant hypertension in patients with obesity. This statement is justified not only for the burden of obesity in this scenario but also for the unmet demands in managing resistant hypertension appropriately by multiple drug-therapy or the lack of real utility of procedures like renal denervation and carotid baroreflex activation.